Ervebo

Ervebo is a recombinant vaccine designed to prevent Ebola virus disease caused by Zaire ebolavirus. It is administered intramuscularly and is manufactured by Merck Sharp & Dohme B.V.

Ervebo is used to provide protection against Ebola virus disease, specifically the Zaire ebolavirus strain. This vaccine is intended for individuals at risk of exposure to the virus, such as healthcare workers and those in outbreak areas. The primary use of Ervebo is to stimulate the immune system to produce antibodies against the Ebola virus.

Common effects of Ervebo may include mild to moderate reactions at the injection site, such as pain, swelling, or redness. Some individuals may experience general symptoms like fatigue, headache, or muscle pain. These effects are typically temporary and resolve on their own.

Ervebo should be administered by healthcare professionals trained in the use of vaccines. It is important to inform your healthcare provider about any allergies or medical conditions before receiving the vaccine. Pregnant women and individuals with weakened immune systems should consult their healthcare provider before vaccination.

There are no specific interactions widely reported with Ervebo. However, it is always advisable to inform your healthcare provider about any medications or supplements you are taking before receiving the vaccine. This helps ensure the safety and effectiveness of the vaccination process.